Brief: FDA Approves Compassionate Use Of Urcosimod (0.05%) For The Treatment Of Neuropathic Corneal Pain
23/01/2026 12:01
Jan 23 (Reuters) - OKYO Pharma Ltd OK11.MU: FDA APPROVES COMPASSIONATE USE OF URCOSIMOD (0.05%) FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN OKYO PHARMA LTD - TO INITIATE 120-PATIENT STUDY OF URCOSIMOD TO TREAT NCP THIS YEAR Source text: ID:nGNXc0qyN Further company coverage: OK11.MU ((Reuters.Briefs@thomsonreuters.com;))
Recent news on OKYO Pharma
See all newsBrief: Okyo Pharma's Chairman Gabriele Cerrone Now Holds 20.55% Of Co's Issued Share Capital
Brief: Okyo Pharma Announces Scientific Advisory Board Meeting And Urcosimod Data Presentation During Ascrs Annual Meeting
Brief: Okyo Pharma Ltd Announces Pricing Of $20 Million Public Offering Of Ordinary Shares
Brief: OKYO Pharma To Offer Up To $200 Million In Securities
Brief: FDA Approves Compassionate Use Of Urcosimod (0.05%) For The Treatment Of Neuropathic Corneal Pain